- Previous Close
155.49 - Open
148.51 - Bid 142.29 x 600
- Ask 144.48 x 200
- Day's Range
140.57 - 150.96 - 52 Week Range
138.51 - 347.72 - Volume
1,662,114 - Avg. Volume
1,039,036 - Market Cap (intraday)
11.528B - Beta (5Y Monthly) 1.24
- PE Ratio (TTM)
14.97 - EPS (TTM)
9.53 - Earnings Date Apr 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
222.88
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
www.iconplc.com41,900
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ICLR
View MorePerformance Overview: ICLR
Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ICLR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ICLR
View MoreValuation Measures
Market Cap
12.57B
Enterprise Value
15.63B
Trailing P/E
16.32
Forward P/E
10.94
PEG Ratio (5yr expected)
0.70
Price/Sales (ttm)
1.56
Price/Book (mrq)
1.32
Enterprise Value/Revenue
1.89
Enterprise Value/EBITDA
9.99
Financial Highlights
Profitability and Income Statement
Profit Margin
9.56%
Return on Assets (ttm)
4.50%
Return on Equity (ttm)
8.44%
Revenue (ttm)
8.28B
Net Income Avi to Common (ttm)
791.47M
Diluted EPS (ttm)
9.53
Balance Sheet and Cash Flow
Total Cash (mrq)
538.79M
Total Debt/Equity (mrq)
37.83%
Levered Free Cash Flow (ttm)
1.09B